These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 20071590)

  • 21. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
    Elhefnawi M; ElGamacy M; Fares M
    BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase.
    Thueng-in K; Thanongsaksrikul J; Jittavisutthikul S; Seesuay W; Chulanetra M; Sakolvaree Y; Srimanote P; Chaicumpa W
    MAbs; 2014; 6(5):1327-39. PubMed ID: 25517317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors.
    Rydberg EH; Cellucci A; Bartholomew L; Mattu M; Barbato G; Ludmerer SW; Graham DJ; Altamura S; Paonessa G; De Francesco R; Migliaccio G; Carfí A
    J Mol Biol; 2009 Jul; 390(5):1048-59. PubMed ID: 19505479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
    Shi ST; Herlihy KJ; Graham JP; Fuhrman SA; Doan C; Parge H; Hickey M; Gao J; Yu X; Chau F; Gonzalez J; Li H; Lewis C; Patick AK; Duggal R
    Antimicrob Agents Chemother; 2008 Feb; 52(2):675-83. PubMed ID: 18070954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
    Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition.
    Biswal BK; Wang M; Cherney MM; Chan L; Yannopoulos CG; Bilimoria D; Bedard J; James MN
    J Mol Biol; 2006 Aug; 361(1):33-45. PubMed ID: 16828488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase.
    Wu JZ; Yao N; Walker M; Hong Z
    Mini Rev Med Chem; 2005 Dec; 5(12):1103-12. PubMed ID: 16375756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nucleoside analog inhibitors of hepatitis C virus replication.
    Carroll SS; Olsen DB
    Infect Disord Drug Targets; 2006 Mar; 6(1):17-29. PubMed ID: 16787301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
    Lam AM; Murakami E; Espiritu C; Steuer HM; Niu C; Keilman M; Bao H; Zennou V; Bourne N; Julander JG; Morrey JD; Smee DF; Frick DN; Heck JA; Wang P; Nagarathnam D; Ross BS; Sofia MJ; Otto MJ; Furman PA
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3187-96. PubMed ID: 20516278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides.
    Cheng CC; Shipps GW; Yang Z; Kawahata N; Lesburg CA; Duca JS; Bandouveres J; Bracken JD; Jiang CK; Agrawal S; Ferrari E; Huang HC
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2119-24. PubMed ID: 20219368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
    Howe AY; Cheng H; Johann S; Mullen S; Chunduru SK; Young DC; Bard J; Chopra R; Krishnamurthy G; Mansour T; O'Connell J
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3327-38. PubMed ID: 18559648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders.
    Eltahla AA; Tay E; Douglas MW; White PA
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7215-24. PubMed ID: 25246395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.
    Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL
    J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.
    Le Pogam S; Kang H; Harris SF; Leveque V; Giannetti AM; Ali S; Jiang WR; Rajyaguru S; Tavares G; Oshiro C; Hendricks T; Klumpp K; Symons J; Browner MF; Cammack N; Nájera I
    J Virol; 2006 Jun; 80(12):6146-54. PubMed ID: 16731953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
    Ahmed-Belkacem A; Ahnou N; Barbotte L; Wychowski C; Pallier C; Brillet R; Pohl RT; Pawlotsky JM
    Gastroenterology; 2010 Mar; 138(3):1112-22. PubMed ID: 19962982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.
    Belema M; Nguyen VN; Romine JL; St Laurent DR; Lopez OD; Goodrich JT; Nower PT; O'Boyle DR; Lemm JA; Fridell RA; Gao M; Fang H; Krause RG; Wang YK; Oliver AJ; Good AC; Knipe JO; Meanwell NA; Snyder LB
    J Med Chem; 2014 Mar; 57(5):1995-2012. PubMed ID: 24437689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mapping cooperative activity of the hepatitis C virus RNA-dependent RNA polymerase using genotype 1a-1b chimeras.
    Gu B; Gutshall LL; Maley D; Pruss CM; Nguyen TT; Silverman CL; Lin-Goerke J; Khandekar S; Liu C; Baker AE; Casper DJ; Sarisky RT
    Biochem Biophys Res Commun; 2004 Jan; 313(2):343-50. PubMed ID: 14684166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection.
    Sims KD; Lemm J; Eley T; Liu M; Berglind A; Sherman D; Lawitz E; Vutikullird AB; Tebas P; Gao M; Pasquinelli C; Grasela DM
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3496-503. PubMed ID: 24733462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current perspective of HCV NS5B inhibitors: a review.
    Patil VM; Gupta SP; Samanta S; Masand N
    Curr Med Chem; 2011; 18(36):5564-97. PubMed ID: 22172066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thumb inhibitor binding eliminates functionally important dynamics in the hepatitis C virus RNA polymerase.
    Davis BC; Thorpe IF
    Proteins; 2013 Jan; 81(1):40-52. PubMed ID: 22855387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.